Genetic test maker 23andMe launches drug R&D effort
by Associated Press
WASHINGTONMar 13, 2015 - 12:00 am GMT+3
by Associated Press
Mar 13, 2015 12:00 am
Google-backed genetic testing company 23andMe is launching its own drug development unit, betting that it can translate its database of customer DNA information into novel medicines. The Silicon Valley-based company announced yesterday that it hired Richard Scheller, a former Genentech executive, to become its chief scientist and lead the company's research and development efforts. Scheller recently retired from a 14-year career with South San Francisco, California-based Genentech, a pioneer of biotech cancer drugs. 23andMe is best known for its saliva-based test kits, which offer users the chance to peek into their genetic code for clues about their ancestral past. But drug research has always been at the foundation of its business model. Much the way social media websites sell advertisers access to their user networks, 23andMe licenses the raw data from its DNA database to researchers. The company has more than 20 partnerships with drug companies including Pfizer and Roche, as well as with government and academic researchers.
Keep up to date with what’s happening in Turkey,
it’s region and the world.
You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.